

Retraction for Alireza Heidari et al., Recent New Results and Achievements of California South University (CSU) BioSpectroscopy Core Research Laboratory for COVID-19 or 2019-nCoV Treatment: Diagnosis and Treatment Methodologies of "Coronavirus"

Alireza Heidari^{1,2*}, Angela Caissutti¹, Maria Henderson¹, Katrina Schmitt¹, Elizabeth Besana¹, Jennifer Esposito¹, Victoria Peterson¹

¹Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA

²American International Standards Institute, Irvine, CA 3800, USA

Reason for Retraction:

The Publisher of Journal of Current Viruses and Treatment Methodologies hereby retracts this article (DOI: 10.14302/issn.2691-8862.jvat-20-3275). After publication, evidence emerged that the corresponding author made unverifiable claims regarding affiliations, credentials, and research outputs. In addition, the peer-review process associated with this article did not meet the rigorous evaluation standards that are fundamental to scholarly publishing. Therefore, the Publisher no longer has confidence in the validity of the results and conclusions. In accordance with the Committee on Publication Ethics (COPE) guidelines, the article will remain publicly accessible but marked clearly as RETRACTED.

It is important to emphasize that this retraction is issued to protect the standards of scientific integrity. The Publisher does not tolerate practices that undermine peer review or mislead the community, and corrective action has been taken to prevent recurrence. We regret any inconvenience this may cause to our readers and reaffirm our commitment to strengthening peer-review mechanisms to ensure all future submissions undergo comprehensive, fair, and consistent evaluation prior to publication.

Corresponding author: Alireza Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, American International Standards Institute, USA. Email: Scholar.Researcher.Scientist@gmail.com

Keywords: Bcr–Abl Tyrosine–Kinase Inhibitors (TKI), Peak Plasmon Absorption, Aggregation, **Coronavirus** Nanoparticles, DNA/RNA, Imatinib (STI571), Nilotinib (AMN107), Dasatinib (BMS–345825), Bosutinib (SKI–606), Ponatinib (AP–24534), Bafetinib (INNO–406)

Received: Mar 16, 2025 **Accepted:** Mar 19, 2020 **Published:** Mar 21, 2020 **Retracted:** Mar 01, 2021